The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles. Fox News Digital spoke ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.